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correlation between the different variables and cardiac 
damage is ongoing. 
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Purpose or Objective: To evaluate the rate of complications 
and the aesthetic outcome in previously irradiated patients 
who underwent mastectomy and subsequent prosthetic 
reconstruction in 2 times. 
 
Material and Methods: Eighty-three patients who underwent 
immediate postmastectomy reconstruction with tissue 
expander between January of 2003 and June of 2012 at the 
Campus Bio-Medico University Hospital in Rome were 
retrospectively divided into two groups: Group A (study 
group) included 30 patients with previous quadrantectomy 
and radiotherapy who underwent salvage mastectomy after 
local recurrence and Group B (control group) included 53 
patients submitted to primary radical mastectomy. Patients 
and disease characteristics were analysed and complications 
were correlated to treatment group. 
 
Results: The median follow-up time for the whole group was 
36 months (range= 12-144 months). Between group A and 
group B, there were no significant differences in terms of 
age, body mass index, comorbidities, pathological stage, 
treatments data (p=NS). In Group A 25/30 patients (83.33%) 
completed heterologous reconstruction. In 5 patients 
(16.67%) a conversion to combined or solely autologous 
reconstruction was needed. In Group B, 52/53 patients 
(98.11%) completed heterologous reconstruction. In 1 case 
(1.88%) the expander was removed due to infection and an 
autologous reconstruction was performed. Revision surgery 
was needed in 5 patients (9.4%). Autologous salvage 
reconstruction was more frequent for Group A patients 
(relative risk 10.4, p=0.02). The overall rate of complications 
was not different between the two groups (66.6% vs 58.5%; 
p=0.49) even if major complications (vast necrosis of 
mastectomy flaps with or without partial implant exposure, 
with or without implant removal, all III and IV-degree 
capsular contractures, either requiring or not requiring 
further surgery) were non significantly higher in the 
irradiated group (53.3% vs 32.0%; p= 0.07). However, 
analysing capsular contracture, a significantly higher risk of 
grade III-IV were recorded in Group A (40% vs 15%; relative 
risk 3.75, p=0.02). In Group A the median time from RT to 
reconstruction was 24 months (range= 9-192 months) and the 
incidence of major complications was not related to time 
from RT to reconstruction (p=0.313).  
 
Conclusion: Heterologus reconstruction after salvage 
mastectomy in previously irradiated patients, is still possible 
with satisfactory results. 
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Purpose or Objective: Germline polymorphisms in oxidative 
stress response genes have been postulated to be involved in 
the development of late normal tissue complications 
following radiotherapy. Despite the key role of mitochondria 
in the production of reactive oxygen species, the contribution 
of mitochondrial DNA variations to clinical radiosensitivity is 
still largely unknown. In the present study, we evaluated the 
association between mitochondrial DNA haplogroups and the 
risk of radiation-induced subcutaneous fibrosis after 
postoperative radiotherapy in breast cancer patients. 
 
Material and Methods: Subcutaneous fibrosis was scored 
according to the Late Effects of Normal Tissue-Subjective 
Objective Management Analytical (LENT-SOMA) scale in 286 
Italian breast cancer patients who received radiotherapy 
after breast conserving surgery. Eight mitochondrial DNA 
(mtDNA) SNPs that define the nine major haplogroups in the 
European population were determined by PCR–RFLP analysis 
on genomic DNA extracted from peripheral blood. 
 
Results: In a Kaplan-Meier analysis evaluated by the log-rank 
test, carriers of haplogroup H were found at lower risk of 
grade ³2 subcutaneous fibrosis (P=0.018). In the multivariate 
Cox regression analysis adjusted for clinical factors (BMI, 
breast diameter, adjuvant treatment, dose per fraction, 
radiation type and acute skin toxicity), the haplogroup H 
emerged as significant protective factor for moderate to 
severe radiation-induced fibrosis (HR: 0.50, 95% CI 0.27-0.92, 
P=0.027). 
 
Conclusion: Our results support a protective role of the 
mitochondrial haplogroup H in the development of radiation-
induced fibrosis in breast cancer patients. Further 
prospective studies with larger sample size and different 
populations are nevertheless warranted to corroborate the 
possible influence of mitochondrial haplogroups on late 
normal tissue radiosensitivity. 
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Purpose or Objective: The Young Boost trial (YBT), a 
multicenter RCT (NCT00212121), investigates whether a 
higher boost dose leads to a lower recurrence rate in young 
patients treated with breast conserving therapy. Cosmetic 
outcome is the secondary objective. The aim of the current 
analysis is to investigate the factors influencing the patients’ 
opinion about cosmesis.  
 
Material and Methods: From 2004-2011, 2421 breast cancer 
patients ≤ 50 yrs were included in The Netherlands, France, 
and Germany. All patients were treated with lumpectomy, 
followed by 50 Gy whole breast irradiation. Patients were 
randomized to receive a standard 16 Gy (n=1211) or a high 26 
Gy boost (n=1210) to the tumour bed. Cosmetic outcome data 
at 4 years of 807 patients were used for the current analysis 
according to the following two scoring systems:  
1. BCCT.core: Digital photographs were analyzed using a 
software program to extract an overall cosmetic score: 
excellent, good, fair or poor. This score is based on 
symmetry, skin color and scar visibility. The 7 features of 
symmetry in the BCCT.core program are: nipple position 
(pBRA), level of lower breast contour (pLBC), level of nipple 
(pUNR), distance from nipple to inframammary fold (pBCE), 
length of breast contour (pBCD), area of the breast (pBAD) 
and non-overlapping area between left and right breast 
(pBOD). 2. Patients’ score using a validated patient’s 
questionnaire about the breast appearance, including an 
overall score: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied. First, we analyzed the 7 
features of BCCT.core in a proportional odds model, to 
